Literature DB >> 25319711

The difference between medicine and magic is that magicians know what they are doing.

Rodney J Hicks1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25319711     DOI： 10.1007/s00259-014-2928-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  33 in total

1.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Authors:  Roelf Valkema; Stanislas A Pauwels; Larry K Kvols; Dik J Kwekkeboom; Francois Jamar; Marion de Jong; Raffaella Barone; Stephan Walrand; Peter P M Kooij; Willem H Bakker; Janet Lasher; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

2.  The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.

Authors:  T W Barber; M S Hofman; B N J Thomson; R J Hicks
Journal:  Eur J Surg Oncol       Date:  2011-09-08       Impact factor: 4.424

3.  Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.

Authors:  M de Jong; E J Rolleman; B F Bernard; T J Visser; W H Bakker; W A Breeman; E P Krenning
Journal:  J Nucl Med       Date:  1996-08       Impact factor: 10.057

Review 4.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

5.  Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Authors:  Samer Ezziddin; Mared Attassi; Charlotte J Yong-Hing; Hojjat Ahmadzadehfar; Winfried Willinek; Frank Grünwald; Stefan Guhlke; Hans-Jürgen Biersack; Amir Sabet
Journal:  J Nucl Med       Date:  2014-01-16       Impact factor: 10.057

6.  Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Authors:  Damian Wild; Melpomeni Fani; Richard Fischer; Luigi Del Pozzo; Felix Kaul; Simone Krebs; Richard Fischer; Jean E F Rivier; Jean Claude Reubi; Helmut R Maecke; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2014-06-24       Impact factor: 10.057

7.  Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.

Authors:  Raghava Kashyap; Michael S Hofman; Michael Michael; Grace Kong; Timothy Akhurst; Peter Eu; Diana Zannino; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-11       Impact factor: 9.236

8.  Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice.

Authors:  Xiaoqing Pan; Norio Suzuki; Ikuo Hirano; Shun Yamazaki; Naoko Minegishi; Masayuki Yamamoto
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

9.  Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system.

Authors:  Jean-Mathieu Beauregard; Michael S Hofman; Jucilene M Pereira; Peter Eu; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2011-06-15       Impact factor: 3.909

10.  Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).

Authors:  G Kong; M Thompson; M Collins; A Herschtal; M S Hofman; V Johnston; P Eu; M Michael; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-21       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.